Index by author
May 01, 2010; Volume 85,
From Bedside to Bench: The Role of Anti-Tumor Necrosis Factor Agents in the Management of Immune-Mediated Inflammatory Diseases
B
BERNSTEIN, CHARLES N.
- You have accessEpidemiology of Immune-Mediated Inflammatory Diseases: Incidence, Prevalence, Natural History, and ComorbiditiesHANI EL-GABALAWY, LYN C. GUENTHER and CHARLES N. BERNSTEINThe Journal of Rheumatology Supplement May 1 2010, 85 2-10; DOI: https://doi.org/10.3899/jrheum.091461
BRESSLER, BRIAN
- You have accessOptimizing Use of Tumor Necrosis Factor Inhibitors in the Management of Immune-Mediated Inflammatory DiseasesBRIAN BRESSLER, BOULOS HARAOUI, EDWARD KEYSTONE and ALESSANDRO SETTEThe Journal of Rheumatology Supplement May 1 2010, 85 40-52; DOI: https://doi.org/10.3899/jrheum.091464
E
EL-GABALAWY, HANI
- You have accessPathophysiology and Pathogenesis of Immune-Mediated Inflammatory Diseases: Commonalities and DifferencesPROTON RAHMAN, ROBERT D. INMAN, HANI EL-GABALAWY and DENIS O. KRAUSEThe Journal of Rheumatology Supplement May 1 2010, 85 11-26; DOI: https://doi.org/10.3899/jrheum.091462
- You have accessEpidemiology of Immune-Mediated Inflammatory Diseases: Incidence, Prevalence, Natural History, and ComorbiditiesHANI EL-GABALAWY, LYN C. GUENTHER and CHARLES N. BERNSTEINThe Journal of Rheumatology Supplement May 1 2010, 85 2-10; DOI: https://doi.org/10.3899/jrheum.091461
G
GUENTHER, LYN C.
- You have accessEpidemiology of Immune-Mediated Inflammatory Diseases: Incidence, Prevalence, Natural History, and ComorbiditiesHANI EL-GABALAWY, LYN C. GUENTHER and CHARLES N. BERNSTEINThe Journal of Rheumatology Supplement May 1 2010, 85 2-10; DOI: https://doi.org/10.3899/jrheum.091461
H
HARAOUI, BOULOS
- You have accessFrom Bedside to Bench: The Role of Anti-Tumor Necrosis Factor Agents in the Management of Immune-Mediated Inflammatory DiseasesBOULOS HARAOUI, ANTHONY S. RUSSELL and EDWARD C. KEYSTONEThe Journal of Rheumatology Supplement May 1 2010, 85 1; DOI: https://doi.org/10.3899/jrheum.091460
- You have accessOptimizing Use of Tumor Necrosis Factor Inhibitors in the Management of Immune-Mediated Inflammatory DiseasesBRIAN BRESSLER, BOULOS HARAOUI, EDWARD KEYSTONE and ALESSANDRO SETTEThe Journal of Rheumatology Supplement May 1 2010, 85 40-52; DOI: https://doi.org/10.3899/jrheum.091464
I
INMAN, ROBERT D.
- You have accessPathophysiology and Pathogenesis of Immune-Mediated Inflammatory Diseases: Commonalities and DifferencesPROTON RAHMAN, ROBERT D. INMAN, HANI EL-GABALAWY and DENIS O. KRAUSEThe Journal of Rheumatology Supplement May 1 2010, 85 11-26; DOI: https://doi.org/10.3899/jrheum.091462
K
KEYSTONE, EDWARD
- You have accessOptimizing Use of Tumor Necrosis Factor Inhibitors in the Management of Immune-Mediated Inflammatory DiseasesBRIAN BRESSLER, BOULOS HARAOUI, EDWARD KEYSTONE and ALESSANDRO SETTEThe Journal of Rheumatology Supplement May 1 2010, 85 40-52; DOI: https://doi.org/10.3899/jrheum.091464
KEYSTONE, EDWARD C.
- You have accessFrom Bedside to Bench: The Role of Anti-Tumor Necrosis Factor Agents in the Management of Immune-Mediated Inflammatory DiseasesBOULOS HARAOUI, ANTHONY S. RUSSELL and EDWARD C. KEYSTONEThe Journal of Rheumatology Supplement May 1 2010, 85 1; DOI: https://doi.org/10.3899/jrheum.091460
- You have accessTumor Necrosis Factor and Anti-Tumor Necrosis Factor TherapiesEDWARD C. KEYSTONE and CARL F. WAREThe Journal of Rheumatology Supplement May 1 2010, 85 27-39; DOI: https://doi.org/10.3899/jrheum.091463
KRAUSE, DENIS O.
- You have accessPathophysiology and Pathogenesis of Immune-Mediated Inflammatory Diseases: Commonalities and DifferencesPROTON RAHMAN, ROBERT D. INMAN, HANI EL-GABALAWY and DENIS O. KRAUSEThe Journal of Rheumatology Supplement May 1 2010, 85 11-26; DOI: https://doi.org/10.3899/jrheum.091462
R
RAHMAN, PROTON
- You have accessPathophysiology and Pathogenesis of Immune-Mediated Inflammatory Diseases: Commonalities and DifferencesPROTON RAHMAN, ROBERT D. INMAN, HANI EL-GABALAWY and DENIS O. KRAUSEThe Journal of Rheumatology Supplement May 1 2010, 85 11-26; DOI: https://doi.org/10.3899/jrheum.091462
ROSENBAUM, JAMES T.
- You have accessAnti-Tumor Necrosis Factor Therapies in Immune-Mediated Rheumatic Diseases. Other Observations from the ClinicANTHONY S. RUSSELL and JAMES T. ROSENBAUMThe Journal of Rheumatology Supplement May 1 2010, 85 53-62; DOI: https://doi.org/10.3899/jrheum.091465
RUSSELL, ANTHONY S.
- You have accessFrom Bedside to Bench: The Role of Anti-Tumor Necrosis Factor Agents in the Management of Immune-Mediated Inflammatory DiseasesBOULOS HARAOUI, ANTHONY S. RUSSELL and EDWARD C. KEYSTONEThe Journal of Rheumatology Supplement May 1 2010, 85 1; DOI: https://doi.org/10.3899/jrheum.091460
- You have accessAnti-Tumor Necrosis Factor Therapies in Immune-Mediated Rheumatic Diseases. Other Observations from the ClinicANTHONY S. RUSSELL and JAMES T. ROSENBAUMThe Journal of Rheumatology Supplement May 1 2010, 85 53-62; DOI: https://doi.org/10.3899/jrheum.091465
S
SETTE, ALESSANDRO
- You have accessOptimizing Use of Tumor Necrosis Factor Inhibitors in the Management of Immune-Mediated Inflammatory DiseasesBRIAN BRESSLER, BOULOS HARAOUI, EDWARD KEYSTONE and ALESSANDRO SETTEThe Journal of Rheumatology Supplement May 1 2010, 85 40-52; DOI: https://doi.org/10.3899/jrheum.091464
W
WARE, CARL F.
- You have accessTumor Necrosis Factor and Anti-Tumor Necrosis Factor TherapiesEDWARD C. KEYSTONE and CARL F. WAREThe Journal of Rheumatology Supplement May 1 2010, 85 27-39; DOI: https://doi.org/10.3899/jrheum.091463